HK1161082A1 - 用於治療再灌注損傷的方法 - Google Patents

用於治療再灌注損傷的方法

Info

Publication number
HK1161082A1
HK1161082A1 HK12101453.4A HK12101453A HK1161082A1 HK 1161082 A1 HK1161082 A1 HK 1161082A1 HK 12101453 A HK12101453 A HK 12101453A HK 1161082 A1 HK1161082 A1 HK 1161082A1
Authority
HK
Hong Kong
Prior art keywords
methods
reperfusion injuries
treating reperfusion
treating
injuries
Prior art date
Application number
HK12101453.4A
Other languages
English (en)
Inventor
Andrei V Gudkov
Robert Fairchild
Original Assignee
克里夫蘭生物實驗室公司
克里夫蘭臨床基金會
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 克里夫蘭生物實驗室公司, 克里夫蘭臨床基金會 filed Critical 克里夫蘭生物實驗室公司
Publication of HK1161082A1 publication Critical patent/HK1161082A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
HK12101453.4A 2008-08-01 2012-02-15 用於治療再灌注損傷的方法 HK1161082A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8576608P 2008-08-01 2008-08-01
PCT/US2009/052493 WO2010014957A1 (en) 2008-08-01 2009-07-31 Methods for treating reperfusion injuries

Publications (1)

Publication Number Publication Date
HK1161082A1 true HK1161082A1 (zh) 2012-08-24

Family

ID=41610763

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12101453.4A HK1161082A1 (zh) 2008-08-01 2012-02-15 用於治療再灌注損傷的方法

Country Status (11)

Country Link
US (4) US8324163B2 (zh)
EP (1) EP2320948B1 (zh)
JP (1) JP5577337B2 (zh)
CN (1) CN102170911B (zh)
AU (1) AU2009276357B2 (zh)
CA (1) CA2732763A1 (zh)
EA (1) EA020579B1 (zh)
ES (1) ES2412237T3 (zh)
HK (1) HK1161082A1 (zh)
PT (1) PT2320948E (zh)
WO (1) WO2010014957A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2460534A1 (en) 2004-12-22 2012-06-06 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof
CN102170911B (zh) * 2008-08-01 2014-07-02 克里夫兰生物实验室公司 用于治疗再灌注损伤的方法
KR20140030132A (ko) 2011-01-10 2014-03-11 클리브랜드 바이오랩스, 아이엔씨. 암을 치료하기 위한 톨-유사 수용체 효능제의 용도
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
US20150328284A1 (en) * 2012-04-02 2015-11-19 Cleveland Biolabs, Inc Compositions and methods comprising toll like receptor (tlr) stimulating agents for prophylaxis and therapy for damage to dermal epithelium
US10202426B2 (en) * 2014-07-30 2019-02-12 Genome Protection, Inc. Flagellin compositions and uses
EP3206708B1 (en) 2014-10-16 2022-11-02 Cleveland Biolabs, Inc. Methods and compositions for the treatment of radiation-related disorders
IL300767A (en) * 2016-08-11 2023-04-01 Univ Temple Regional ischemia/reperfusion injury
KR20200031144A (ko) 2017-07-20 2020-03-23 스포겐 바이오테크 인코포레이티드 식물 보호, 성장 및 생산성 향상을 위한 생물활성 폴리펩타이드
CN208752357U (zh) * 2018-09-21 2019-04-16 合肥京东方显示光源有限公司 背光模块及具有该背光模块的显示面板及显示器
KR102524577B1 (ko) 2019-04-22 2023-04-21 전남대학교산학협력단 플라젤린 융합 단백질 및 이의 용도

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5399494A (en) 1983-03-04 1995-03-21 The University Of Maryland System Vibrio cholerae strain CVD103Hgr, method of making same, and vaccines derived therefrom
US6130082A (en) 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
EP0503012B1 (de) 1990-09-28 1996-06-26 Sulzer Innotec Ag Hohlnadel zur medizinischen verwendung und verfahren zur herstellung derartiger hohlnadeln
AU3630093A (en) 1992-03-02 1993-10-05 Biocine S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
US5693476A (en) 1995-02-24 1997-12-02 The Board Of Trustees Of The Leland Stanford Junior University Methods of screening for compounds capable of modulating vesicular release
US20020009747A1 (en) 1997-08-25 2002-01-24 Freda Diane Miller Methods and reagents for identifying modulators of neuronal apoptosis
US5994409A (en) 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
WO2001040280A2 (en) 1999-11-29 2001-06-07 Inotek Corporation Composition and method for treating a microbial infection
EP1254174B1 (en) 2000-01-31 2007-04-25 Munin Corporation Human cyr61
US7300749B2 (en) 2000-02-17 2007-11-27 Millennium Pharmaceuticals, Inc. Molecules of the pyrin domain protein family and uses thereof
WO2002044363A1 (en) 2000-11-28 2002-06-06 Genesis Research And Development Corporation Limited Methods for modulating apoptotic cell death
ATE463505T1 (de) 2001-04-20 2010-04-15 Inst Systems Biology Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren
US8703146B2 (en) 2001-04-20 2014-04-22 Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
CA2462638A1 (en) 2001-10-02 2003-04-10 University Of Chicago Methods and compositions for modulating apoptosis
US7078165B2 (en) 2003-03-27 2006-07-18 Institut Pasteur Method for modulating Nod1 activity, use of a MTP related molecule for modulating Nod1 activity, and therapeutic applications thereof
US7638485B2 (en) 2003-12-02 2009-12-29 Cleveland Biolabs, Inc. Modulating apoptosis
WO2005056054A2 (en) 2003-12-02 2005-06-23 Cleveland Clinic Foundation METHODS OF INHIBITING APOPTOSIS USING INDUCERS OF NF-κB
WO2005056041A2 (en) 2003-12-02 2005-06-23 Cleveland Clinic Foundation METHODS OF INHIBITING APOPTOSIS USING LATENT TGFβ
CN1913915B (zh) 2003-12-02 2010-12-01 克里夫兰临床基金会 使用鞭毛蛋白防止辐射的方法
US20050266391A1 (en) 2004-01-15 2005-12-01 Bennett Brydon L Methods for preserving tissue
WO2006081007A2 (en) 2004-12-16 2006-08-03 Wake Forest University Health Sciences Use of flagellin in tumor immunotherapy
EP2460534A1 (en) 2004-12-22 2012-06-06 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof
US20090306190A1 (en) * 2005-09-09 2009-12-10 Mary Stenzel-Poore Neuroprotectants
WO2007070623A2 (en) 2005-12-14 2007-06-21 Medistem Laboratories, Inc. Transcatheter tumor immunoembolization
AU2007239095B2 (en) 2006-01-09 2012-05-03 The Regents Of The University Of California Immunostimulatory combinations for vaccine adjuvants
EP2114427B1 (en) 2007-01-30 2014-06-25 New York University Peptides for treatment of conditions associated with nitric oxide
EP2178896A1 (en) 2007-07-31 2010-04-28 The Johns Hopkins University Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
EA026990B1 (ru) 2007-11-07 2017-06-30 Селлдекс Терапьютикс Инк. Антитела, связывающиеся с человеческой клеткой dec-205
WO2009102818A1 (en) 2008-02-11 2009-08-20 Cleveland Biolabs, Inc. Method for reducing the effects of chemotheraphy using flagellin related polypeptides
CN102170911B (zh) 2008-08-01 2014-07-02 克里夫兰生物实验室公司 用于治疗再灌注损伤的方法
AU2010303464B2 (en) 2009-10-06 2014-05-01 Panacela Labs Llc Use of toll-like receptor and agonist for treating cancer

Also Published As

Publication number Publication date
PT2320948E (pt) 2013-06-17
CA2732763A1 (en) 2010-02-04
US20110135665A1 (en) 2011-06-09
JP2011529922A (ja) 2011-12-15
WO2010014957A1 (en) 2010-02-04
US20130004515A1 (en) 2013-01-03
US9006180B2 (en) 2015-04-14
ES2412237T3 (es) 2013-07-10
CN102170911A (zh) 2011-08-31
US20150182587A1 (en) 2015-07-02
EP2320948B1 (en) 2013-03-06
EA020579B1 (ru) 2014-12-30
US20140220037A1 (en) 2014-08-07
AU2009276357B2 (en) 2014-09-11
EP2320948A4 (en) 2012-01-25
JP5577337B2 (ja) 2014-08-20
EA201170294A1 (ru) 2011-08-30
US8618059B2 (en) 2013-12-31
AU2009276357A1 (en) 2010-02-04
EP2320948A1 (en) 2011-05-18
CN102170911B (zh) 2014-07-02
US8324163B2 (en) 2012-12-04

Similar Documents

Publication Publication Date Title
IL257418A (en) Methods for treating addiction
HK1161082A1 (zh) 用於治療再灌注損傷的方法
IL212348A0 (en) Treatment method
IL209895A0 (en) Compounds for treating beta-amyloidoses
HK1167082A1 (zh) 治療局部缺血和缺血-再灌注損傷的組合物與方法
HUE053476T2 (hu) Eszköz gastrooesophagealis reflux betegség kezelésére
PT2248083T (pt) Método de autenticação
IL213619A0 (en) Treatment
GB0802116D0 (en) Treatment
EP2282826A4 (en) PROCESS FOR TREATMENT OF ODOR
GB0822011D0 (en) Treatment
IL211774A (en) Animal Care Device
HK1203516A1 (zh) 治療乾癬的方法
EP2311711A4 (en) CONTROL UNIT
EP2341936A4 (en) METHOD FOR TREATING OR PREVENTING IL-1ß-CONTAINED ILLNESSES
GB0801209D0 (en) Process
EP2453896A4 (en) PROCESS FOR TREATING SCHIZOPHRENIA
GB0811992D0 (en) Treatment
GB0800875D0 (en) Process
EP2296461A4 (en) METHODS OF TREATING ARTHROPODS
EP2292495A4 (en) STEERING APPARATUS
GB0820972D0 (en) Treatment
IL213287A0 (en) Treatment for glomerulonephritis
GB0805912D0 (en) Treatment
ZA201000867B (en) Methods for treating dependence

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180731